Business Context and Reporting Period
Company: NewGenIVF Group Ltd (NIVF)
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: NewGenIVF is an assisted reproductive services (ARS) provider operating clinics in Thailand, Cambodia, and Kyrgyzstan. The company is undergoing a significant strategic transformation from a pure-play fertility provider to a diversified conglomerate, adding operations in real estate development (UAE), digital asset management (Solana staking), and mining. The company completed a SPAC business combination in April 2024 and has executed multiple reverse stock splits in 2025 and 2026 to maintain Nasdaq listing compliance.
Key Financial Metrics
| Metric | 2025 (USD) | 2024 (USD) |
|---|---|---|
| Total Revenue | $4,726,433 | $5,433,375 |
| Gross Profit | $955,846 | $1,826,894 |
| Gross Margin | 20.2% | 33.6% |
| Operating Loss | $(10,726,461) | $(1,160,495) |
| Net Income | $9,728,723 | $(474,101) |
| Cash and Cash Equivalents | $758,621 | $457,740 |
| Working Capital | $5,017,221 | $452,391 |
| Convertible Notes Outstanding | $5,289,000 | $5,207,625 |
Note: 2025 Net Income is primarily driven by a non-cash bargain purchase gain of $21.65 million from acquisitions, masking a significant operating loss.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue decreased 13.0% to $4.73 million. IVF treatment revenue dropped 28.1% to $3.91 million due to management changes in Thailand and the ramp-up of a new Kyrgyzstan clinic. However, the company launched a new Fertility Referral Services segment, generating $820,570 in revenue (17.4% of total).
- Margin Compression: Gross margin contracted from 33.6% to 20.2% due to increased unit service costs and reorganization of subcontractor models, despite a slight increase in total cost of revenue.
- Operating Expense Surge: Operating expenses increased 291% to $11.68 million. This was driven by $1.86 million in professional fees for a UAE real estate project, $2.91 million in staff/director salaries (including bonuses for maintaining Nasdaq listing), and $1.1 million in write-offs.
- Acquisition Gains: The company recognized a $21.65 million bargain purchase gain from the acquisitions of MicroSort Lab Services and Nodexus Inc., turning a net loss in 2024 into a net profit in 2025.
- Digital Asset Losses: The company recorded a net loss of $332,480 on digital assets (Solana) due to market volatility, holding 13,000 SOL tokens at year-end with an unrealized loss of approximately $1.28 million.
Guidance, Outlook, and Risks
Management Commentary and Strategy
Management is pivoting the company into a diversified conglomerate. Key initiatives include:
- Solana Strategy: Plans to invest up to $30 million in staking Solana (SOL) tokens over 18 months to generate yield and capital appreciation. As of the filing date, the company holds 10,000 SOL tokens with an unrealized loss.
- Real Estate: Entered a joint venture in Ras Al Khaimah, UAE, with a projected net return of up to $67 million, though only a reservation deposit has been paid to date.
- Technology Licensing: Acquired MicroSort and Nodexus technologies to expand into high-margin technology licensing for gender selection and cell sorting.
Material Risks and Contingencies
- Going Concern: The filing explicitly states the company may not be able to continue as a going concern. Cash reserves are approximately $758,621, and the company relies on external financing (convertible notes and equity lines) to bridge liquidity shortfalls.
- Listing Compliance: The company has executed six reverse stock splits between February 2025 and March 2026 to maintain the $1.00 minimum bid price required by Nasdaq. Failure to maintain this price could result in immediate delisting.
- Geopolitical Instability: Operations in Thailand, Cambodia, and Kyrgyzstan face risks from regional conflicts (including a reported war between Thailand and Cambodia in late 2025) and the US-Israel-Iran conflict, which disrupts travel and oil supplies.
- Regulatory & Legal: The CEO and CMO faced arrest in Hong Kong in 2025 regarding alleged violations of the Human Reproductive Technology Ordinance (gender selection/surrogacy). While charges were not laid within the limitation period for the initial arrest, a summons was served on the CEO in October 2025 regarding commercial surrogacy arrangements.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective as of December 31, 2025, citing a material weakness due to a lack of adequately skilled staff with U.S. GAAP knowledge.
Investor Verification Checklist
- Verify Liquidity Runway: Confirm the status of the $5.27 million in outstanding convertible promissory notes and the $100 million equity line of credit with White Lion Capital to assess immediate solvency.
- Validate Bargain Purchase Gains: Scrutinize the $21.65 million non-cash gain from MicroSort and Nodexus acquisitions to ensure the fair value assessments of intangible assets are robust and not inflated.
- Monitor Nasdaq Compliance: Track the stock price relative to the $1.00 minimum bid price requirement, given the history of multiple reverse splits and previous deficiency notices.
- Assess Digital Asset Exposure: Review the valuation and custody of the Solana holdings, noting the significant unrealized losses and the risks associated with the staking strategy.
- Review Legal Proceedings: Monitor the outcome of the summons served on the CEO regarding Hong Kong surrogacy laws and any potential impact on the company's ability to operate in key markets.
- Confirm Internal Control Remediation: Verify the hiring of U.S. GAAP-skilled staff and the implementation of new financial reporting controls to address the identified material weakness.